First, P/LP variants in genes without an established association with breast cancer predisposition were found in 15.4% of the patients with a positive test result (4.1% in PMS2, 3% in MUTYH, 2% in MEN1, and 1% in NTHL1, RAD50, SDHA, SUFU, DICER1 and BLM1), equivalent to 4.2% of the overall study population. This evidence concerns the gene RAD50 and breast carcinoma.